Representation and Medication Use in Juvenile Idiopathic Arthritis
RUMAJI
1 other identifier
observational
36
1 country
1
Brief Summary
According to the International League of Associations for Rheumatology classification, Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of arthritis of unknown cause and with onset before 16 years of age, characterized by joint inflammation lasting for 6 or more weeks. Few studies exist regarding the care experience of children affected by this rheumatic condition. On the other hand, methotrexate and biologics constitute the primary treatment for children with JIA. As with adults undergoing the same treatment, adherence is critical. Difficulties for children to take the drugs have been reported. Notwithstanding, if adherence promotion in pediatric chronic conditions has been the subject of recommendations with regard to care management, the investigators lack information to understand the grounds for adherence specifically in JIA. In order to understand and decipher the parent-child adherence mechanisms and practices, the RUMAJI study will be conducted. Indeed, improving the relational approach between children and their caregivers as well as unrestricted drug adherence involves researching and understanding how appropriation of the disease and treatment could be achieved.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedFirst Submitted
Initial submission to the registry
March 18, 2019
CompletedFirst Posted
Study publicly available on registry
March 27, 2019
CompletedApril 29, 2019
March 1, 2019
6 months
March 18, 2019
April 25, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Interview with parents
Interview with parents to learn about role of parents in the management of juvenile idiopathic arthritis in their children
1 day
Secondary Outcomes (2)
Interview with children
1 day
Interview with physicians
1 day
Study Arms (3)
Physicians
3 paediatricians and 3 rheumatologists
Parents
Parents
Children
Children
Interventions
Interviews with parents of children with juvenile idiopathic arthritis
Interviews with children with juvenile idiopathic arthritis
Eligibility Criteria
Children with JIA and their parents
You may qualify if:
- all JIA forms
- all treatment type (NSAIDs, MTX, bDMARDs)
You may not qualify if:
- \- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Uhmontpellier
Montpellier, 34295, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jean-David COHEN, MD
University Hospital, Montpellier
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 18, 2019
First Posted
March 27, 2019
Study Start
April 1, 2017
Primary Completion
October 1, 2017
Study Completion
December 1, 2017
Last Updated
April 29, 2019
Record last verified: 2019-03